Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
27 studies found for:    "Churg Strauss syndrome"
Show Display Options
Rank Status Study
1 Unknown  Mepolizumab As a Steroid-Sparing Treatment Option in the Churg Strauss Syndrome
Condition: Churg Strauss Syndrome
Intervention: Biological: Mepolizumab
2 Unknown  CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors
Condition: Churg-Strauss Syndrome
Interventions: Drug: azathioprine;   Drug: cyclophosphamide
3 Terminated
Has Results
Rituxan in Churg Strauss Syndrome With Renal Involvement
Condition: Churg-Strauss Syndrome
Interventions: Drug: Rituximab;   Drug: Prednisone
4 Completed Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome
Condition: Churg Strauss Syndrome
Intervention: Drug: mepolizumab
5 Not yet recruiting Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome
Condition: Churg-Strauss Syndrome
Intervention: Biological: HPC cell infusion
6 Completed A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
Condition: Churg-Strauss Syndrome
Interventions: Biological: Mepolizumab;   Drug: Placebo
7 Recruiting Determining Disease Activity Biomarkers in Individuals With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
Conditions: Eosinophilic Granulomatosis With Polyangiitis;   Churg-Strauss Syndrome
Intervention:
8 Not yet recruiting Rituximab in Eosinophilic Granulomatosis With Polyangiitis
Condition: Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Interventions: Drug: Rituximab;   Drug: Placebo-rituximab;   Drug: Cyclophosphamide;   Drug: Placebo-cyclophosphamide
9 Completed Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)
Conditions: MPA;   PAN or EGPA With FFS=0;   At Diagnosis or Within the First 15 Days Following Initiation of Corticosteroids
Interventions: Drug: corticosteroid and azathioprine;   Drug: corticosteroid and placebo
10 Not yet recruiting Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Condition: Asthma
Intervention: Drug: Reslizumab
11 Active, not recruiting PRO Development for ANCA Associated Vasculitis
Conditions: Wegener Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome
Intervention:
12 Completed RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
Conditions: Wegener's Granulomatosis;   Churg-Strauss Syndrome;   Microscopic Polyangiitis
Interventions: Drug: Infliximab;   Drug: Rituximab
13 Unknown  Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides
Conditions: Wegener's Granulomatosis;   Churg-Strauss Syndrome;   Microscopic Polyangiitis;   Polyarteritis Nodosa
Interventions: Drug: Methotrexate;   Drug: Cyclophosphamide
14 Completed Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
Conditions: Hypereosinophilic Syndromes;   Eosinophilic Gastroenteritis;   Churg-Strauss Syndrome;   Eosinophilic Esophagitis
Intervention: Drug: Mepolizumab
15 Completed Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
Conditions: Vasculitis;   Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome;   Polyarteritis Nodosa
Interventions: Drug: prednisone, methylprednisolone,cyclophosphamides;   Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;   Drug: Mycophenolate mofetil,methotrexate
16 Active, not recruiting The ANCA Vasculitis Questionnaire (AAV-PRO©)
Conditions: Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA);   Churg-Strauss Syndrome (CSS);   Granulomatosis With Polyangiitis (Wegener's) (GPA);   Wegener Granulomatosis (WG);   Microscopic Polyangiitis (MPA);   ANCA-Associated Vasculitis (AAV);   Vasculitis
Intervention: Other: Online questionnaire
17 Unknown  Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
Conditions: Purpura, Schoenlein-Henoch;   Graft Versus Host Disease;   Anemia, Hemolytic, Autoimmune;   Rheumatoid Arthritis;   Churg-Strauss Syndrome;   Hypersensitivity Vasculitis;   Wegener's Granulomatosis;   Systemic Lupus Erythematosus;   Giant Cell Arteritis;   Pure Red Cell Aplasia;   Juvenile Rheumatoid Arthritis;   Polyarteritis Nodosa;   Autoimmune Thrombocytopenic Purpura;   Takayasu Arteritis
Interventions: Drug: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: filgrastim;   Drug: methylprednisolone;   Drug: prednisone;   Procedure: Autologous Peripheral Blood Stem Cell Transplantation
18 Recruiting VCRC Tissue Repository
Conditions: Aortitis;   Cutaneous Vasculitis;   Eosinophilic Granulomatosis With Polyangiitis;   Giant Cell Arteritis;   Granulomatosis With Polyangiitis (Wegener's);   Henoch-Schonlein Purpura;   IgA Vasculitis;   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu Arteritis;   Churg-Strauss Syndrome
Intervention:
19 Recruiting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Conditions: Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg Strauss Syndrome;   Polyarteritis Nodosa;   Giant Cell Arteritis;   Takayasu Arteritis
Intervention:
20 Recruiting Pediatric Vasculitis Initiative
Conditions: Wegeners Granulomatosis (Granulomatosis With Polyangiitis);   Microscopic Polyangiitis;   Churg Strauss Syndrome (Eosinophilic Granulomatosis With Polyangiitis);   Polyarteritis Nodosa;   Takayasu Arteritis;   Primary CNS Vasculitis;   Unclassified Vasculitis
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-27) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.